Gilead Sciences Inc. (GILD) Q3 (USD) Adj. EPS 2.55 (exp. 2.19), Revenue 8.30bln (exp. 7.80bln)

• Sees FY Adj. loss/shr 0.85-1.20 (exp. loss 0.40)

The print itself is a clean beat on both lines, but the FY guide pointing to an adjusted loss per share, well wider than consensus, is the element that has historically driven the reaction in single-name pharma reports of this shape. The usual sequence in such cases is that the headline beat fades within the opening minutes while the desk works out what sits behind the guidance: a one-off charge such as an acquired in-process R&D write-down tied to a deal, which the market typically looks through, versus an operating deterioration in the core franchise, which it does not. Gilead's prior form is relevant here: the name has a track record of large acquisition-related charges distorting GAAP and adjusted guidance in the quarter a deal closes, and traders will be scanning the release and the call for exactly that line item. The spread between the quarterly beat and the guided full-year loss implies a heavily back-loaded or charge-laden Q4, so the reconciliation walk on the call is the tell. Given the stock's weight in the large-cap biotech complex, past episodes have shown read-across to the group is limited unless the driver is operational rather than deal-related.